The Mechanism of β-N-methylamino-l-alanine Inhibition of tRNA Aminoacylation and Its Impact on Misincorporation by Han, Nien-Ching et al.
Chapman University 
Chapman University Digital Commons 
Biology, Chemistry, and Environmental Sciences 
Faculty Articles and Research 
Science and Technology Faculty Articles and 
Research 
1-31-2021 
The Mechanism of β-N-methylamino-l-alanine Inhibition of tRNA 
Aminoacylation and Its Impact on Misincorporation 
Nien-Ching Han 
Tammy J. Bullwinkle 
Kaeli F. Loeb 
Kym F. Faull 
Kyle Mohler 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.chapman.edu/sees_articles 
 Part of the Amino Acids, Peptides, and Proteins Commons, Medical Neurobiology Commons, 
Medicinal and Pharmaceutical Chemistry Commons, Medicinal-Pharmaceutical Chemistry Commons, 
Nervous System Diseases Commons, Neurology Commons, Neurosciences Commons, and the Other 
Chemistry Commons 
The Mechanism of β-N-methylamino-l-alanine Inhibition of tRNA Aminoacylation 
and Its Impact on Misincorporation 
Comments 
This article was originally published in Journal of Biological Chemistry, volume 295, issue 5, in 2021. 
https://doi.org/10.1016/S0021-9258(17)49898-X 
Creative Commons License 




Nien-Ching Han, Tammy J. Bullwinkle, Kaeli F. Loeb, Kym F. Faull, Kyle Mohler, Jesse Rinehart, and Michael 
Ibba 
Themechanism of -N-methylamino-L-alanine inhibition of
tRNA aminoacylation and its impact onmisincorporation
Received for publication,October 30, 2019, and in revised form, December 10, 2019 Published, Papers in Press, December 20, 2019, DOI 10.1074/jbc.RA119.011714
Nien-Ching Han‡, Tammy J. Bullwinkle‡, Kaeli F. Loeb‡, Kym F. Faull§, Kyle Mohler¶, X Jesse Rinehart¶,
and Michael Ibba‡1
From the ‡Department of Microbiology, The Ohio State University, Columbus, Ohio 43220, §PasarowMass Spectrometry
Laboratory, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral
Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90024–1759,
¶Department of Cellular andMolecular Physiology, Yale University, NewHaven, Connecticut 06520, and Systems Biology Institute,
Yale University, New Haven, Connecticut 06520
Edited by Ronald C. Wek
-N-methylamino-L-alanine (BMAA) is a nonproteinogenic
amino acid that has been associatedwithneurodegenerative dis-
eases, including amyotrophic lateral sclerosis (ALS) andAlzhei-
mer’s disease (AD). BMAA has been found in human protein
extracts; however, the mechanism by which it enters the pro-
teome is still unclear. It has been suggested that BMAA is mis-
incorporated at serine codons during protein synthesis, but
direct evidence of its cotranslational incorporation is currently
lacking. Here, using LC-MS–purified BMAA and several bio-
chemical assays, we sought to determine whether any amino-
acyl-tRNA synthetase (aaRS) utilizes BMAA as a substrate for
aminoacylation. Despite BMAA’s previously predicted misin-
corporation at serine codons, following a screen for amino acid
activation inATP/PPi exchange assays, we observed that BMAA
is not a substrate for human seryl-tRNA synthetase (SerRS).
Instead, we observed that BMAA is a substrate for human ala-
nyl-tRNA synthetase (AlaRS) and can form BMAA-tRNAAla by
escaping from the intrinsic AlaRS proofreading activity. Fur-
thermore,we found that BMAA inhibits both the cognate amino
acid activation and the editing functions of AlaRS. Our results
reveal that, in addition to being misincorporated during trans-
lation, BMAA may be able to disrupt the integrity of protein
synthesis through multiple different mechanisms.
-N-methylamino-L-alanine (BMAA)2 is a nonproteino-
genic amino acid that was first isolated from the seeds of the
cycad species Cycas circinalis (1). BMAA acts as a glutamate
agonist when bicarbonated under physiological conditions,
causing excitotoxicity in neurons (2). The correlation between
BMAA and neurodegeneration was initially observed in Guam,
where the rate of ALS-Parkinson’s (ALS-parkinsonism-demen-
tia complex) symptoms was 50- to 100-fold higher than the
average within the continental United States and other devel-
oped countries (3). Because the symptoms were geographically
restricted, the etiology of disease was considered to be related
to the unique lifestyle of the indigenous Chamorro people. It
was noticed that the Chamorros regularly consumed tortillas
made from cycad seeds; therefore, BMAA was proposed to be
the cause of the Guam symptom (4). However, it was later
found that the concentrations of BMAA in the tortillaswere not
sufficient to achieve the observed toxicity (5). The hypothesis of
BMAA being the cause of the Guam ALS-parkinsonism-de-
mentia complex cases was not further investigated until 2003,
when bioaccumulation of BMAA was identified in the Guam
dietary chain by Cox et al. (6). Accumulated BMAA was found
not only in the free amino acid pool, but also in the protein-
associated fraction of the foods (7). Since then, studies have
explored the question of how BMAA enters or associates with
the proteome. In 2013, Dunlop et al. (8) revealed that BMAA
competes with serine for incorporation and suggested that it
enters the proteome during protein synthesis at serine codons.
However, this hypothesis is still debated, and themechanism of
BMAA misincorporation remains unclear.
Although the number of ALS-parkinsonism-dementia com-
plex cases has significantly declined in Guam, BMAA is still a
widespread problem. Environmental factors such as BMAA
accumulation are believed to play important roles in the devel-
opment of sporadic ALS and AD (9–11). BMAA is synthesized
by cyanobacteria and algae, and it has been found inmany bod-
ies of water all over the world (12–14). Both ocean and fresh-
water animals have been shown to contain BMAA, including
commonly consumed seafood (15, 16). As BMAA has previ-
ously been shown to bioaccumulate through an isolated dietary
chain, elevated incidence of eutrophication in domestic and
international waters makes BMAA contamination a worldwide
health concern. Therefore, there is an urgent need to under-
stand the mechanism of BMAA protein incorporation.
For a substrate to be incorporated during de novo protein
synthesis, it must be aminoacylated on a tRNA by an amino-
acyl-tRNA synthetase (aaRS). aaRSs are essential enzymes cat-
alyzing the aminoacylation reaction through a two-step
process: first, the amino acid is activated to form an aminoacyl-
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adenylate (AA-AMP); then theAA-AMP is transferred to the 3
end of the corresponding tRNA. Accurate aminoacylation is
required for faithful translation of the encoded genetic infor-
mation. However, because of the structural similarities ofmany
amino acids, errors in amino acid activation can occur (17). For
example, AlaRS misacylates both Ser and Gly onto tRNAAla.
Fortunately, these enzymes have evolved a proofreading (edit-
ing) function to hydrolyzemisactivated amino acids ormisami-
noacylated tRNAs (18). The loss of proofreading function can
be detrimental to cells because of the accumulation of mis-
folded and malfunctional proteins (19).
In this study, we found that BMAA is a substrate for human
AlaRS (HsAlaRS), and is not subject to the AlaRS intrinsic
proofreading activity. Furthermore, we showed that BMAAcan
inhibit both the activation and editing catalytic efficiency of
HsAlaRS, revealing newmechanisms by which BMAA can dis-
rupt the integrity of protein synthesis.
Results
BMAA is a substrate of human AlaRS
To identify the aaRS catalyzing BMAA aminoacylation, an
initial screen to examine BMAA activation was performed.
Because it was previously suggested that SerRS is responsible
for aminoacylating BMAA (8), we monitored amino acid
activation using ATP/PPi exchange assays with recombinant
human SerRS, AlaRS, and prolyl-tRNA synthetase (ProRS),
respectively. ATP/PPi exchange is an assay estimating the level
of substrate activation by measuring the production of radiola-
beled ATP in the presence of excess [32P]PPi in the reaction.
AlaRS andProRSwere chosen because theymisacylate noncog-
nate amino acids that are either serine or share a structural
similarity with serine (Fig. 1A): AlaRS can misacylate Gly and
Ser to tRNAAla (20), whereas ProRS misacylates Ala and Cys to
tRNAPro (21). Chromatographically purified BMAA was used
throughout the study to eliminate any artificial effects because
of amino acid contamination. Among the aaRSs examined, only
HsAlaRS was able to activate BMAA (Fig. 1B). To further elu-
cidate the kinetics of BMAA misactivation, the steady-state
activation kinetics of HsAlaRS for Ala, Ser, and BMAA were
determined (Table 1). The results showed that BMAA shares a
similarKm to the knownAlaRS noncognate amino acid, Ser, but
the kcat was 40-fold lower than Ser, revealing that the rate of
BMAA-AMP formation was comparatively slow. Because ami-
noacylation is a two-step process, we further investigated
whether BMAA can be transferred to tRNAAla to form BMAA-
tRNAAla. BMAA proved to be a substrate for AlaRS amino-
acylation, resulting in 3.5% of active tRNAAla being
charged with BMAA (Fig. 1, C and D). Besides the no amino
acid negative control as a background, we also tested pheny-
lalanine as a noncognate amino acid and no aminoacylation
was observed (Fig. S2).
To understand if codon-specific misincorporation of BMAA
can be observed in vivo, we usedMS-READ, anMS-based mis-
incorporation reporter technique, to investigate BMAAmisin-
corporation at Ala codons in yeast (22). However, no BMAA
misincorporation was identified in our reporter (Fig. S3). We
also examined if BMAA is excluded from the cyanobacterial
translational machinery, as it is a cyanotoxin. We performed
the activation screen using AlaRS from Anabaena pcc.7120, a
model nitrogen-fixing cyanobacterial species, and found that
Figure 1. BMAA is a substrate of human AlaRS. A, the chemical structure of Ser, Ala, and BMAA. B, ATP/PPi exchange assays were carried out using three
humanaaRSs, respectively: ProRS, SerRS, andAlaRS to screen for BMAAactivation.C, aminoacylation assayswere carriedoutusing [32P]-labeledhuman tRNAAla
and WT HsAlaRS in the presence of 50 mM BMAA and 0.1 mM Ala. A no amino acid control was also conducted to determine the background level. D, relative
level of charged tRNA at 30minwas determinedby normalizing the results to Ala-tRNAAla after subtracting the background value of the no amino acid control.
All of the experiments were done at least three times, and the error bars indicate the standard deviations of the means.
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similar to HsAlaRS, AnaAlaRS is able to activate BMAA (Fig.
S4).
BMAA is not subject to AlaRS intrinsic editing
The consequence of AlaRS misaminoacylation is evolution-
arily problematic; hence, cells have developed redundant
mechanisms to solve this problem (18). Two checkpoints exist
to prevent the accumulation of Ser-tRNAAla. One is the intrin-
sic editing domain in AlaRS, which is able to deacylate Ser-
tRNAAla both in cis and in trans (20); another is AlaXP, the
genome encoded free-standing AlaRS editing domain homolog
that is able to hydrolyze mischarged tRNAAla in trans (23). An
editing-deficient AlaRS variant (HsAlaRS C723A) was used to
determine the role of proofreading on BMAA activation and
aminoacylation. HsAlaRS is highly similar tomouse AlaRS, and
the humanCys-723 residue corresponds to the previously char-
acterized mouse Cys-723 (24) and the Escherichia coli Cys-666
(20) residues in the editing domain, both of which are critical
for editing (Fig. S1). Our results showed no significant differ-
ences in BMAA activation and aminoacylation between the
WT AlaRS and the C723A editing-deficient variant (Fig. 2, A
and B). This was further supported by the activation kinetics
performed with C723A, whose kinetic parameters toward
BMAA activation showed no significant differences from the
WT enzyme’s (Table 1). To exclude any possible artifacts of
using the C723A variant, we carried out an ATP-consumption
assay using the WT AlaRS enzyme as reported previously (25).
Measuring the consumption of ATP is an indirect measure of
pre- and post-transfer editing because of ATP futile cycling as a
consequence of iterative rounds of substrate activation and
product hydrolysis. If a substrate is subject to proofreading,
higher levels of ATP consumption should be observed. We
tested ATP consumption using Ala, Ser, and BMAA, with or
without the presence of tRNAAla tomonitor both pre- andpost-
transfer editing. The futile cycling of ATP was only observed
with Ser, indicating that it is subject to both pre- and post-
transfer editing as reported previously (26). The level of ATP
consumption with BMAA was similar to Ala, supporting the
observation with C723A that BMAA is not subject to HsAlaRS
proofreading (Fig. 2C).
BMAA is a competitive inhibitor of AlaRS activation of Ala
As presented earlier in the activation kinetics data with
AlaRS and C723A (Table 1), we noticed that the Km of BMAA
activation is similar to Ser, but the rate of product formation is
extremely low. This led us to investigate whether BMAA could
act as an activation inhibitor of HsAlaRS by sequestering
enzyme from its cognate substrate. In general, there are three
modes of reversible enzyme inhibition: Competitive, uncom-
petitive and noncompetitive. The mode of inhibition can be
characterized by the change of Km and Vmax in the presence of
the inhibitor (27). To establish BMAA’s mode of inhibition, the
inhibition kinetics were measured to estimate the Km and Vmax
of AlaRS cognate amino acid activation in the presence of
BMAA. Upon BMAA treatment, the Km of AlaRS activation
increased whereas the Vmax was unaffected, suggesting that
BMAA is a competitive inhibitor of HsAlaRS (Fig. 3A). Inhibi-
tion assays were then carried out using two different concen-
trations of BMAA and the data were analyzed on a Lineweaver-
Burk plot. The results demonstrated that with increasing
concentration of the inhibitor, the slopes increased, and the
y-intercept remained unchanged, confirming that BMAA is
indeed a competitive inhibitor (Fig. 3B). The inhibition con-
stantKI is defined as the concentration required to produce half
of themaximum inhibition, and hence is used to represent how
potent an inhibitor is. Here, we determined the KI of BMMA in
inhibiting amino acid activation by AlaRS to be 25.8 mM using
the equation KI Km [I]/(Km, apparent Km).
BMAA perturbs the proofreading function of AlaRS
The role of BMAA as an enzyme inhibitor has recently been
shown by vanOnselen et al. (28), wheremultiple enzymes were
exposed to BMAA and the activity was evaluated via commer-
cially available kits. The authors found that BMAA tends to
inhibit enzymes with exposed amino acids sharing terminal
hydroxyl groups. The editing domain of AlaRS is composed of
three critical residues, Ser-587, Thr-567 and Cys-666 (E. coli
numbering) (29). As serine and threonine both have terminal
hydroxyl groups, we were curious if the editing domain is also
sensitive to BMAA treatment. To explore this hypothesis, we
performed deacylation assays using misacylated Ser-tRNAAla
and estimated the efficiency of deacylation by HsAlaRS follow-
ing BMAA treatment. A 2.4-fold increase in the half-life of Ser-
tRNAAla following BMAA treatment was observed (Fig. 4 and
Table S1), showing that BMAA perturbs the intrinsic AlaRS
editing activity.
Discussion
BMAA misincorporation is facilitated through AlaRS
Mistranslation generates aberrant or misfolded protein and
can eventually result in protein aggregation, which is a feature
of many neurodegenerative diseases including Alzheimer’s and
Parkinson’s (30). Neurons are notably sensitive to erroneous
translation; for example, a minor defect in AlaRS editing can
lead to neurodegeneration in mice (19). Thus, many neurode-
generative diseases have been associated with mutations in the
protein synthesis machinery (31). We attempted to observe
codon-specific misincorporation of BMAA at Ala codons in
yeast using MS-READ (22), but failed to identify any BMAA
misincorporation at the resolution at which our reporter was
capable of detecting (Fig. S3). A previous report was also unable
to detect BMAA misincorporation in human cell lines when
examining SDS-PAGE-purified proteins (32). Because these
experiments were conducted in growth media supplemented
Table 1
Steady-state activation kinetics of HsAlaRS and C723A
ATP/PPi exchange assays were carried out to determine the activation kinetics. The
specificity is defined by the ratio of kcat/Km of cognate over noncognate amino acids.
C723A activation kinetics is also compared with the WT AlaRS to examine if dif-
ferences exist between these two enzymes.
Km (mM) kcat (s1) kcat/Km (s1 mM1) Specificity
AlaRS Ala 0.04 0.01 4 0.3 100 1
Ser 25 3 6 1.6 0.2 500
BMAA 38 16 0.15 0.06 0.004 25,000
C723A Ala 0.06 0.01 8 2 131 0.8
Ser 31 10 6 0.6 0.2 500
BMAA 19 12 0.07 0.02 0.004 25,000
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with 4 mM and 2 mM BMAA respectively, the frequency of
BMAAmisincorporation may be too low to be detected, which
is consistentwith our biochemical assayswhich onlymonitored
a low fraction (3.5%) of BMAA-tRNAAla formation using 50mM
BMAA. Although we found that BMAA is a rather weak sub-
strate for HsAlaRS aminoacylation, it is able to escape the
intrinsic proofreading mechanism of AlaRS. Thus, low level
misincorporation may still accumulate throughout the lifespan
of the individual and eventually become problematic, as the
capability for cells to maintain proteostasis declines over the
course of aging (33).
Because it was reported in 2013 that BMAA competes with
Ser for cellular incorporation, others have tried to observe Ser
codon misincorporation by in vitro translation, but the out-
come remains controversial (8). Glover et al. (34) used the
PURE system to investigate the efficiency of BMAA misincor-
poration to replace nine different amino acids by quantifying
Figure 4. BMAA perturbs AlaRS editing. A deacylation assay using [3H]Ser-
tRNAAla is carried out with 1 mM HsAlaRS, 1 mM HsAlaRS with 50 mM BMAA, 1
mM C723A, and a no enzyme control. The percentage of misacylated tRNA
remaining in the reaction is calculated at each time point. The counts of time
point zerowas set as 100% for the deacylation analysis. All of the experiments
were done at least three times, and the error bars indicate the standard devi-
ations of the means.
Figure 2. BMAA is not subject to AlaRS proofreading. A, pyrophosphate exchange assay using human AlaRS and the AlaRS editingmutant C723A in the
presence of 50mM BMAA. B, BMAA aminoacylation is carried out using 500 nM C723A. C, an ATP consumption assay is used to examine ATP futile cycling
with and without the presence of tRNAAla. All of the experiments were done at least three times, and the error bars indicate the standard deviations of
the means.
Figure 3. BMAA is a competitive inhibitor toAlaRS activation. A, steady-state activation kinetics is performedwith orwithout 25mMBMAA, and the results
were used to calculate the kinetics of inhibition. B, aminoacylation assays were carried out with 100 nM human AlaRS in the presence of 12.5 mM (filled circles),
25 mM (filled squares), or no BMAA (filled triangles), and plotted on a Lineweaver-Burk plot to identify the mode of inhibition.
BMAA disrupts the function of human AlaRS
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total protein in the reaction and found that the highest substi-
tution occurred with Ala and Ser. However, a recent work by
Beri et al. (35) had failed to identify protein synthesis in the
reaction lacking Ser (Ser  BMAA). These contradicting
results have raised doubts on the hypothesis of BMAA misin-
corporation at Ser codons.We showed here that BMAA is not a
substrate for HsSerRS but instead for HsAlaRS. The competi-
tion observed previously may be because of other reasons, such
as BMAA competing with Ser for aminoacylation by AlaRS (1);
TCAprecipitated protein was used in the previous study, so the
interaction of BMAA and peptides may not be covalent (2);
other amino acid contaminants existing in commercial BMAA
products may interfere with the experiments (3).
Although considered a cyanotoxin, the biosynthesis and
functions of BMAA in cyanobacteria are still unclear. It was
reported that BMAA is produced under nitrogen-limiting con-
ditions in Synechocystis, whereas exogenous BMAA inhibits
nitrogenase activity and the formation of heterocysts (special-
ized cells that perform nitrogen fixation) inAnabaena (36–38).
Using the AlaRS from Anabaena pcc.7120, we found that
AnaAlaRS also activates BMAA (Fig. S4). It is unknown if mis-
translation or inhibition of aaRS activity contributes to the fail-
ure of heterocyst development.
BMAA perturbs HsAlaRS function through multiple pathways
Nonproteinogenic amino acids (NPAs) are amino acids that
are not naturally encoded in the genome. Many of them share
structural similarities with cognate amino acids, hence aremis-
recognized by aaRS, leading to misincorporation. NPAs are
often more toxic than naturally encoded noncognate amino
acids, because they are not evolutionarily involved in the trans-
lational machinery and have a higher chance to elude intrinsic
quality control mechanisms. For example, azetidine-2-carbox-
ylic acid (Aze), an NPA found in sugar beets, is reported to
misincorporate at Pro codons by evading ProRS quality control
(26). Many NPAs generate cellular toxicity in vivo, which is
believed to be a consequence of mistranslation (39). Here we
reported that the toxicity of BMAA to AlaRS is achieved
throughmultiple pathways (Fig. 5).We showed that in addition
to misincorporation, BMAA acts as a competitive inhibitor to
HsAlaRS activation and perturbs the editing function of the
enzyme. By targeting the activation pocket, cognate amino acid
activation is inhibited, potentially resulting in the activation of
multiple stress response pathways. For example, halofuginone,
a ProRS active site competitive inhibitor, is reported to induce
the GCN2 pathway because of the accumulation of deacylated
tRNA in the cells (40). When GCN2 is activated by post-trans-
lational phosphorylation, it inhibits the eukaryotic translation
initiation factor 2 (eIF2), leading to the reduction of global
translation. It is unclear if a similar effect may occur in BMAA-
treated cells.
In addition to inhibitingAlaRS amino acid activation, BMAA
also perturbs the deacylation activity of HsAlaRS on Ser-
tRNAAla. It is well-documented that AlaRS editing is crucial in
mammals. As it was recently reported, a vertebrate-specific
protein ANKRD16 was identified to facilitate the pre-transfer
editing of AlaRS, suggesting that mistranslation by AlaRS is
evolutionarily problematic (41, 42). In eukaryotes, the endo-
plasmic reticulum (ER) is responsible for facilitating appropri-
ate protein folding, and the loss of aaRS quality control can lead
to ER stress (43, 44). To alleviate the stress, the unfolded protein
response is triggered, where protein synthesis is halted, and the
expression of chaperones is increased. If the ER stress is still
unable to be resolved, apoptosis will be activated. Up-regula-
tion of ER stress andunfolded protein response gene expression
have both been reported in cells treated with BMAA (35), sup-
porting the finding in our study that BMAA possesses the
potential to perturb faithful protein synthesis.
Materials andmethods
BMAA purification
BMAA (Sigma, B107–50 mg) was dissolved in water (1.3 ml)
and aliquots (250l) were injected onto a reversed phaseHPLC
column system (Keystone Scientific Aquasil C18, 250 10mm
connected in series to a Keystone Scientific C18 250  4.6
mm column) equilibrated in water/TFA (100/0.1) and eluted
isocratically (0.5 ml/min) with the same solution. UV absorp-
tion of the eluate was monitored (215 and 280 nm) and col-
lected fractions (0.5 min) were screened off-line for BMAA,
Ala, and Ser content. This was done by first drying aliquots of
the collected fractions (typically 10 l) in a vacuum centrifuge
and treating them firstwithmethanolicHCl tomake themethyl
esters and then with acetic anhydride to make the N-acetyl
derivatives. The fully derivatized samples, along with authentic
Ser and Ala standards, were analyzed by combined GC/MS.
Neither Ser nor Ala (as the N-acetylmethyl esters) was detected
in the peak BMAA-containing fractions, which were then
pooled. Aliquots were taken of the final pooled BMAA sample
and screened again by GC/MS for verification of the absence of
Ser and Ala contamination. Again, no contamination of Ser or
Ala was detected in the final pooled BMAA sample that was
then dried in a vacuum centrifuge. The BMAA content of the
final sample was determined by weighing.
Strains, plasmids, and genetic techniques
Anabaena PCC 7120 was grown on BG11 plates until a visi-
ble lawn formed. Genomic DNA was extracted as previously
reported with modification of the lysis method (45) in which
the cells were frozen in liquid nitrogen and then crushed and
ground using a mortar and pestle while still immersed in liquid
Figure 5. A model for BMAA’s impact on protein synthesis. We showed
that BMAA affects the function of AlaRS via multiple mechanisms, which
could potentially lead to disrupting the stability of protein synthesis. Besides
acting as a noncognate substrate for misincorporation, it also perturbs the
activation and editing function of AlaRS.
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nitrogen. The resulting powder was resuspended in 400 l TE
buffer with 0.5% SDS, followed by the purification process
reported by Singh et al. (45). The human AlaRS-pET21b
(Rosetta (DE3)) and human ProRS-pET21b (BL21(DE3)) con-
structs are gifts from Dr. Karin Musier-Forsyth at The Ohio
State University. The EcAlaRS, and AnaAlaRS expression con-
struct were made by Gibson, assembling the PCR product of
AlaRS-encoding genes from the genomic DNA to NdeI and
Xho1 digested pET21b. The fusion proteins were overex-
pressed in BL21(DE3). The human SerRS-pQE80 expression
construct was a gift from Dr. Miljan Simonović from The Uni-
versity of Illinois atChicago (46). Site-directedmutagenesiswas
used to generate the EcC666A and HsC723A overexpression
construct.
Protein expression and purification
All the fusion protein expression constructs were grown
overnight in lysogeny broth with the corresponding antibiotics
based on the selection markers. The overnight cultures were
back-diluted in the same media at 1:100 and induced when the
optical density reached 0.4–0.6 with 0.5 mM isopropyl 1-thio-
-D-galactopyranoside (IPTG) at 16 °C overnight except
C666A, which was induced at 37 °C for 4 h with 1 mM IPTG.
Cells were then harvested by centrifugation (5000 g, 20 min)
and resuspended in 10 ml lysis buffer containing 50 mM Tris-
HCl, pH 8.0, 300mMNaCl, 10mM imidazole, and half a tablet of
the cOmpleteTM EDTA-free protease inhibitor mixture
(Roche) before being subjected to sonication. The homogenate
was centrifuged (75,000  g, 20 min, twice), and the superna-
tant was first filtered through a 0.22-M filter disk then sub-
jected to affinity column purification using TALON® metal
affinity resin (Takara) for His-tag protein purification. The col-
umn was pre-equilibrated with 20 resin bed volumes of wash
buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 10 mM imidaz-
ole) before loading the sample, followed by another wash with
20 resin bed volumes of wash buffer. The fusion protein was
eluted with 2 resin bed volumes of elution buffer (50 mM Tris-
HCl, pH 8.0, 300 mM NaCl and 250 mM imidazole), and the
collected fractions were screened by SDS-PAGE. Fractions of
interest were concentrated; dialyzed against 20 mM Tris-HCl,
pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, and 10% glyc-
erol overnight; and followed by a second dialysis for 4 h using
the same buffer with 20% glycerol. The concentrations of active
enzymes were determined by active site titration as described
previously (47).
tRNA preparation and radiolabeling
tRNAAla was transcribed by T7 polymerase in 40 mM Tris,
pH 8.0, 2 mM spermidine, 22 mM MgCl2, 5 mM DTT, 50 g/ml
BSA, 20 mM 5GMP, pyrophosphatase, 4 mM NTP, RNase
inhibitor, and 50g templateDNAat 42 °C for 12–16 h.DEAE-
cellulose anionic exchange resin was used for tRNA purifica-
tion and was pre-equilibrated with 20 mM Tris, pH 8.0, and 5
mMMgCl2. After the in vitro transcribed samplewas loaded, the
column was washed in the same buffer with 250 mM NaCl and
eluted with 1 M NaCl. The eluted fractions were pooled and
incubated at20 °C overnight in 3 volumes of ice-cold ethanol
and 0.1 volume of 3 M sodium acetate (pH 5.5). After centrifu-
gation (4500  g, 10 min) the supernatant was decanted, and
the pellet was air-dried. Finally, the purified tRNA pellet was
resuspended in water, and the active concentration was deter-
mined through aminoacylation assays as described below. The
[3-32P]-labeled tRNAAla was prepared as described previously
with slight modification (48). In this study, the Ala-76 was
removed through in vitro transcription, and this tRNA lacking
the 3 terminal adenine was used for the radiolabel reaction.
The [3-32P]-labeled tRNA was purified by acid phenol chloro-
form extraction, resuspended in water and further purified
with G25 size-exclusion chromatography to remove free
[-32P]ATP. The labeled tRNA was refolded at 70 °C for 2 min
in 5mMMgCl2, and slow-cooled to room temperature. Cognate
amino acid aminoacylation was examined using the TLC
method described below (Fig. S2).
Aminoacylation assay
In general, aminoacylation assays were carried out at 37 °C in
aminoacylation buffer (100 mMNa-HEPES, 30 mM KCl, 10 mM
MgCl2), 4mMATP, 100M radiolabeled amino acid, tRNA, and
aaRS. Time points were taken by spotting aliquots of the reac-
tion onto 3MMWhatman filter disks presoaked with 5% TCA
for quenching. The disks were washed with 5% TCA three
times, ethanol once, and dried in an oven before measuring
the radioactivity by scintillation counting (Beckman Coulter
LS6500). Because not all in vitro transcripts are active, we used
5l stock tRNA and 150 nMHsAlaRS to determine the concen-
tration of active human tRNAAla. Longer time points were
taken to ensure that the tRNAs were saturated with amino
acids, and the highest count was selected for calculating the
active concentration. [32P] tRNAAla was used for the BMAA
aminoacylation assay. 500 nM AlaRS/C723A was added to
initiate the reaction in aminoacylation buffer containing
[32P]tRNA, 10 mM ATP, 10 mMDTT, and the designated
amino acids (100 M Ala/50 mM BMAA/no aa). Aliquots were
quenched at chosen time points by an equal volume of S1 mix
(1 S1 buffer, 0.5 M sodium acetate, pH 4.5, and S1 nuclease).
Reactions were incubated at room temperature for 30 min and
aliquots were spotted on a PEI cellulose TLC plate (Sigma-Al-
drich). Free [-32P]AMP and aminoacyl [-32P]AMPwere sep-
arated by developing the TLCwith 100mM ammonium acetate
and 5% acetic acid. The TLC plate was imaged by Typhoon
FLA9000 phosphorimager (GE Healthcare), and the intensity
was analyzed using ImageJ. The fraction of charged tRNA was
determined by the ratio of charged/uncharged tRNA as described
previously (49) after subtracting the background values of the no
amino acid control. The results were normalized to Ala-tRNAAla
to determine the relative level of aminoacylation.
Pyrophosphate exchange
Pyrophosphate exchange assays were carried out at 37 °C in
HKM buffer (100 mM Na-Hepes, pH 7.2, 30 mM KCl, 10 mM
MgCl2, 2 mM NaF) containing 2 mM ATP, 2 mM [32P]PPi (2–4
cpm/pmol) and 500 nM aaRS as described previously (50).
Briefly, the reactions were quenched at designated time points
by aliquoting 25 l into 970 l charcoal solution (1% charcoal,
5.6% HClO4, and 75 mM PPi). The quenched reactions were
deposited on 3MMWhatman filter discs by vacuum filtration,
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followed bywashing three timeswith 5mlwater, oncewith 5ml
EtOH, and dried in the oven. Finally, the radioactivity was
determined by liquid scintillation counting. Results were fit to a
Michaelis-Menten curve using KaleidaGraph to determine the
steady state activation kinetics.
ATP consumption assay
ATP consumption assays were performed as described pre-
viouslywith slightmodification (25). In this study, the assaywas
carried out at 37 °C in aminoacylation buffer containing 100
mM amino acids, 3 mM [-32P]ATP, 2 units/ml of yeast pyro-
phosphatase (Roche), and1 M human AlaRS with or without 2
M tRNA. Reactions were quenched at each time point by ali-
quoting 2-l samples into 2-l glacial acetic acid. Quenched
reaction was spotted on a PEI cellulose plate prewashed with
water, and the separation of [-32P]ATP and [-32P]Pi was
accomplished by developing in 0.7 M potassium phosphate (pH
3.5). The TLC plate was imaged by Typhoon FLA9000 phos-
phorimager (GE Healthcare), and the intensity was analyzed
using ImageJ. The concentration of Pi formation was deter-
mined by multiplying the Pi/ATP ratio with the initial ATP
concentration (3 mM).
Enzyme inhibition assay
To determine the inhibition kinetics, aminoacylation was
carried out in the same condition with 50 mM BMAA and 400,
250, 200, 125,100, 50, 25, or 12.5M [14C]Ala. The radioactivity
was determined by liquid scintillation counting, and the results
were fitted into a Michaelis-Menten curve using KaleidaGraph
asmentioned previously. For the Lineweaver-Burk plot, amino-
acylation was carried out at 37 °C with 50 mM, 25 mM, or no
BMAA in aminoacylation buffer, including 4 mM ATP, 5 M
tRNAAla, 100 nM HsAlaRS, and different concentrations of
[14C]Ala (5, 10, 20, or 40 M).
Misaminoacylation and deacylation
The misaminoacylation reaction was carried out at 37 °C for
1 h in aminoacylation buffer (100 mM Na-HEPES, 30 mM KCl,
10 mM MgCl2) containing 50 M tRNAAla, pyrophosphatase,
800 M [3H]Ser, and 2.5MC666A. Ser-tRNAAla was extracted
by adding 1 volume of acid phenol chloroform, mixing thor-
oughly, and centrifuging at 11,000 g for 5 min. The aqueous
phasewas collected and the tRNAwas precipitated overnight at
80 °C in 2.7 volumes of cold ethanol and 0.1 volumes of sodium
acetate (pH 4.5). The sample was centrifuged at 11,000 g for 30
min, the supernatant was decanted, and the pellet was air-dried
for 10 min. Finally, the pellet was resuspended in 100 mM
sodium acetate (pH 4.5) and was used for the deacylation assay.
Deacylation reactions were carried out at 37 °C in aminoacyla-
tion buffer containing [3H]Ser-tRNAAla and100 nM AlaRS.
C723A was also tested as a negative control. 50 mM BMAAwas
treated to determine the effect of BMAAonAlaRS editing. A no
enzyme control was also included to estimate spontaneous
deacylation. The reactions were quenched at different time
points followed by washing as described previously in the ami-
noacylation section above. Time point zero was taken immedi-
ately prior to addition of the enzyme to initiate the reaction, and
was set as 100% misaminoacylation for downstream analysis.
MS-READ sample preparation
Saccharomyces cerevisiae MS-READ reporter samples were
prepared as previously described with slight modification (22).
Briefly, S. cerevisiae strain KMO3 (51) was transformed with
pXRH3 containing the Ala codonMS-READ reporter. The Ala
codon reporter (GCU) was constructed through site-directed
mutagenesis from the previously described Phe codon MS-
READ reporter (UUU) plasmid (22). The cells were grown with
orwithout 4mMBMAAuntil the outer diameter reached 1, and
was lysed by sonication. TheMS-READ reporter peptides were
purified as described previously (22).
Protein digestion and MS
Affinity-purified, buffer-exchanged proteinwas digested and
analyzed by MS as described previously with some modifica-
tions (22). Briefly, the concentration of protein was determined
by UV280 spectroscopy and 5 g ELP-GFP (MS-READ)
reporter from S. cerevisiae was dissolved in 12.5 l solubiliza-
tion buffer consisting of 10mMTris-HCl, pH 8.5 (23 °C), 10mM
DTT, 1 mM EDTA, and 0.5% acid labile surfactant (ALS-101,
Protea). Samples were heat denatured for 20 min at 55 °C in a
heatblock.Alkylationofcysteineswasperformedwith iodoacet-
amide (IAA) using a final IAA concentration of 24 mM. The
alkylation reaction proceeded for 30 min at room temperature
in the dark. Excess IAAwas quenched with DTT and the buffer
concentration was adjusted using 1 M Tris-HCl, pH 8.5, result-
ing in a final Tris-HCl concentration of 150 mM. The reaction
was then diluted with water and 1 MCaCl2 solution to obtain an
ALS-101 concentration of 0.045% and 2 mM CaCl2, respec-
tively. Finally, sequencing grade porcine trypsin (Promega) was
added to obtain an enyzme/protein ratio of 1/5.3 and the digest
was incubated for 15 h at 37 °Cwithout shaking. The digest was
quenched with 20% TFA solution resulting in a sample pH of 2.
Cleavage of the acid-cleavable detergent proceeded for 15 min
at room temperature. Digests were frozen at 80 °C until fur-
ther processing. Peptides were desalted on C18 UltraMicroSpin
columns (The Nest Group Inc.) essentially following the
instructions provided by the manufacturer but using 300 l
elution solvent consisting of 80% ACN, 0.1% TFA for peptide
elution. Peptides were dried in a vacuum centrifuge at room
temperature. Dried peptides were reconstituted and analyzed
by LC-MS/MS. LC-MS/MS was performed on an Orbitrap
Velos using a Top10 HCD method. The trapping column con-
sisted of a 3 cm  150 m Kasil frit-terminated fused silica
capillary packed with 3 m particle size Reprosil-Pur 120
C18-AQ (Dr. Maisch GmBH). The analytical column was a 20
cm  75 m ID picofrit (New Objective) column packed with
1.9 m particle size Reprosil-Pur 120 C18-AQ (Dr. Maisch
GmBH) to a length of 20 cm. Trapping column and analytical
column were connected using a vented split setup using a low
dead volume T metal connector where the spray voltage was
applied. Eluent A was 0.1% formic acid in water and eluent B
was 0.1% formic acid in acetonitrile. Trapping of peptides was
performed for 5 min at a flow rate of 2.5 l/min with an eluent
composition of 2% eluent B. Gradient separation of peptides
proceeded at a flow rate of 300 nl/min using the following linear
gradient program (min/% eluent B): 0.0/2.0, 0.1/2.0, 60.00/25.0,
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70.0/40, 72.0/95.0, 78.0/95.0, 80.0/2.0, 90.0/2.0. An estimated
150 ng of the digest was injected for each experiment. A data-
base search was performed withMaxQuant v. 1.5.3.30 against a
customdatabase ofGFPX16 containing all natural AAs at posi-
tion X16, and a S. cerevisiae protein database (UniProt, strain
AWRI1631, 5450 sequences). Forward and decoy database
searches were carried out using full trypsin specificity with up
to three missed cleavages and using amass tolerance of 30 ppm
for the precursor and 0.1 Da for fragment ions, respectively.
Peptides were analyzed and quantified in Skyline.
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for the fusion protein expression constructs and P. Kelly for the valu-
able discussions. The Pasarow Mass Spectrometry Laboratory (KFF)
gratefully acknowledges support from Hidden Wings, Solvang, CA.
References
1. Vega, A., and Bell, E. A. (1967) -Amino--methylaminopropionic acid, a
new amino acid from seeds ofCycas circinalis. Phytochemistry 6, 759–762
CrossRef
2. Weiss, J. H., Christine, C. W., and Choi, D. W. (1989) Bicarbonate depen-
dence of glutamate receptor activation by -N-methylamino-L-alanine:
Channel recording and study with related compounds. Neuron 3,
321–326 CrossRef Medline
3. Mulder, D.W., Kurland, L. T., and Iriarte, L. L. (1954) Neurologic diseases
on the island of Guam. U. S. Armed Forces Med. J. 5, 1724–1739 Medline
4. Spencer, P. S., Nunn, P. B., Hugon, J., Ludolph, A. C., Ross, S. M., Roy,
D. N., and Robertson, R. C. (1987) Guam amyotrophic lateral sclerosis-
parkinsonism dementia linked to a plant excitant neurotoxin. Science 237,
517–522 CrossRef Medline
5. Duncan,M.W., Steele, J. C., Kopin, I. J., andMarkey, S. P. (1990) 2-Amino-
3-(methylamino)-propanoic acid (BMAA) in cycad flour: An unlikely
cause of amyotrophic lateral sclerosis and parkinsonism-dementia of
Guam. Neurology 40, 767–772 CrossRef Medline
6. Cox, P. A., Banack, S. A., and Murch, S. J. (2003) Biomagnification of
cyanobacterial neurotoxins and neurodegenerative disease among the
Chamorro people of Guam. Proc. Natl. Acad. Sci. U.S.A. 100,
13380–13383 CrossRef Medline
7. Murch, S. J., Cox, P. A., and Banack, S. A. (2004) A mechanism for slow
release of biomagnified cyanobacterial neurotoxins and neurodegenera-
tive disease in Guam. Proc. Natl. Acad. Sci. U.S.A. 101, 12228–12231
CrossRef Medline
8. Dunlop, R. A., Cox, P. A., Banack, S. A., and Rodgers, K. J. (2013) The
non-protein amino acid BMAA is misincorporated into human proteins
in place of L-serine causing protein misfolding and aggregation. PLoS One
8, e75376 CrossRef Medline
9. Caller, T. A., Field, N. C., Chipman, J. W., Shi, X., Harris, B. T., and Stom-
mel, E. W. (2012) Spatial clustering of amyotrophic lateral sclerosis and
the potential role of BMAA.Amyotroph. Lateral Scler. 13, 25–32CrossRef
Medline
10. Masseret, E., Banack, S., Boumédiène, F., Abadie, E., Brient, L., Pernet, F.,
Juntas-Morales, R., Pageot, N., Metcalf, J., Cox, P., Camu, W., and French
Network on ALS Clusters Detection and Investigation (2013) Dietary
BMAA exposure in an amyotrophic lateral sclerosis cluster from southern
France. PLoS One 8, e83406 CrossRef Medline
11. Torbick, N., Ziniti, B., Stommel, E., Linder, E., Andrew, A., Caller, T.,
Haney, J., Bradley,W., Henegan, P. L., and Shi, X. (2018) Assessing cyano-
bacterial harmful algal blooms as risk factors for amyotrophic lateral scle-
rosis. Neurotox. Res. 33, 199–212 CrossRef Medline
12. Cox, P. A., Banack, S. A., Murch, S. J., Rasmussen, U., Tien, G., Bidigare,
R. R., Metcalf, J. S., Morrison, L. F., Codd, G. A., and Bergman, B. (2005)
Diverse taxa of cyanobacteria produce -N-methylamino-L-alanine, a
neurotoxic amino acid. Proc. Natl. Acad. Sci. U.S.A. 102, 5074–5078
CrossRef Medline
13. Al-Sammak, M. A., Hoagland, K. D., Cassada, D., and Snow, D. D. (2014)
Co-occurrence of the cyanotoxins BMAA, DABA and anatoxin-a in Ne-
braska reservoirs, fish, and aquatic plants. Toxins (Basel). 6, 488–508
CrossRef Medline
14. Esterhuizen, M., and Downing, T. G. (2008) -N-methylamino-L-alanine
(BMAA) in novel South African cyanobacterial isolates. Ecotoxicol. Envi-
ron. Saf. 71, 309–313 CrossRef Medline
15. Davis, D. A.,Mondo, K., Stern, E., Annor, A. K.,Murch, S. J., Coyne, T.M.,
Brand, L. E., Niemeyer, M. E., Sharp, S., Bradley, W. G., Cox, P. A., and
Mash, D. C. (2019) Cyanobacterial neurotoxin BMAA and brain pathol-
ogy in stranded dolphins. PLoS One 14, e0213346 CrossRef Medline
16. Jiang, L., Kiselova, N., Rosén, J., and Ilag, L. L. (2014) Quantification of
neurotoxin BMAA (-N-methylamino-L-alanine) in seafood from Swed-
ish markets. Sci. Rep. 4, 6931 CrossRef Medline
17. Mohler, K., and Ibba, M. (2017) Translational fidelity and mistranslation
in the cellular response to stress. Nat. Microbiol. 2, 17117 CrossRef
Medline
18. Guo,M., Chong, Y. E., Shapiro, R., Beebe, K., Yang, X. L., and Schimmel, P.
(2009) Paradox of mistranslation of serine for alanine caused by AlaRS
recognition dilemma. Nature 462, 808–812 CrossRef Medline
19. Lee, J. W., Beebe, K., Nangle, L. A., Jang, J., Longo-Guess, C. M., Cook,
S. A., Davisson, M. T., Sundberg, J. P., Schimmel, P., and Ackerman, S. L.
(2006) Editing-defective tRNA synthetase causes protein misfolding and
neurodegeneration. Nature 443, 50–55 CrossRef Medline
20. Beebe, K., Ribas De Pouplana, L., and Schimmel, P. (2003) Elucidation of
tRNA-dependent editing by a class II tRNA synthetase and significance
for cell viability. EMBO J. 22, 668–675 CrossRef Medline
21. Wong, F.-C., Beuning, P. J., Nagan, M., Shiba, K., and Musier-Forsyth, K.
(2002) Functional role of the prokaryotic proline-tRNA synthetase inser-
tion domain in amino acid editing. Biochemistry 41, 7108–7115 CrossRef
Medline
22. Mohler, K., Aerni, H. R., Gassaway, B., Ling, J., Ibba, M., and Rinehart, J.
(2017)MS-READ: Quantitative measurement of amino acid incorpora-
tion. Biochim. Biophys. Acta Gen. Subj. 1861, 3081–3088 CrossRef
Medline
23. Chong, Y. E., Yang, X. L., and Schimmel, P. (2008) Natural homolog of
tRNA synthetase editing domain rescues conditional lethality caused by
mistranslation. J. Biol. Chem. 283, 30073–30078 CrossRef Medline
24. Liu, Y., Satz, J. S., Vo, M.-N., Nangle, L. A., Schimmel, P., and Ackerman,
S. L. (2014) Deficiencies in tRNA synthetase editing activity cause cardio-
proteinopathy.Proc. Natl. Acad. Sci. 111, 17570–17575CrossRefMedline
25. Roy, H., Ling, J., Irnov, M., and Ibba, M. (2004) Post-transfer editing in
vitro and in vivo by the  subunit of phenylalanyl-tRNA synthetase.
EMBO J. 23, 4639–4648 CrossRef Medline
26. Song, Y., Zhou, H., Vo, M.-N., Shi, Y., Hussain Nawaz, M., Vargas-Rodri-
guez, O., Diedrich, J. K., Yates, J. R., Kishi, S., Musier-Forsyth, K., and
Schimmel, P. (2017) Double mimicry evades tRNA synthetase editing by
toxic vegetable-sourced non-proteinogenic amino acid. Nat. Commun. 8,
2281 CrossRef Medline
27. Dixon, M., andWebb, E. C. (1979) Enzymes, 3rd Ed., 332–352,Academic
Press, New York
28. van Onselen, R., and Downing, T. G. (2018) BMAA-protein interactions:
A possible new mechanism of toxicity. Toxicon 143, 74–80 CrossRef
Medline
29. Pawar, K. I., Suma, K., Seenivasan, A., Kuncha, S. K., Routh, S. B., Krupa-
rani, S. P., and Sankaranarayanan, R. (2017) Role of D-aminoacyl-tRNA
deacylase beyond chiral proofreading as a cellular defense against glycine
mischarging by AlaRS. Elife 6, e24001 CrossRef Medline
BMAA disrupts the function of human AlaRS
J. Biol. Chem. (2020) 295(5) 1402–1410 1409
30. Selkoe, D. J. (2004) Cell biology of protein misfolding: The examples of
Alzheimer’s and Parkinson’s diseases. Nat. Cell Biol. 6, 1054–1061
CrossRef Medline
31. Kapur, M., and Ackerman, S. L. (2018) MRNA translation gone awry:
Translation fidelity and neurological disease. Trends Genet. 34, 218–231
CrossRef Medline
32. van Onselen, R., Downing, S., Kemp, G., and Downing, T. (2017) Investi-
gating -N-methylamino-L-alanine misincorporation in human cell cul-
tures: A comparative study with known amino acid analogues. Toxins 9,
E400 CrossRef Medline
33. Saez, I., andVilchez, D. (2014) Themechanistic links between proteasome
activity, aging and age-related diseases. Curr. Genomics. 15, 38–51
CrossRef Medline
34. Glover, W. B., Mash, D. C., andMurch, S. J. (2014) The natural non-protein
amino acid N--methylamino-L-alanine (BMAA) is incorporated into pro-
tein during synthesis. Amino Acids 46, 2553–2559 CrossRef Medline
35. Beri, J., Nash, T., Martin, R. M., and Bereman, M. S. (2017) Exposure to
BMAAmirrors molecular processes linked to neurodegenerative disease.
Proteomics 17, 170061 CrossRef Medline
36. Downing, S., Banack, S. A., Metcalf, J. S., Cox, P. A., and Downing, T. G.
(2011) Nitrogen starvation of cyanobacteria results in the production of
-N-methylamino-L-alanine. Toxicon 58, 187–194 CrossRef Medline
37. Berntzon, L., Erasmie, S., Celepli, N., Eriksson, J., Rasmussen, U., and
Bergman, B. (2013) BMAA inhibits nitrogen fixation in the cyanobacte-
rium Nostoc sp. PCC 7120. Mar. Drugs 11, 3091–3108 CrossRef Medline
38. Popova, A. A., Rasmussen, U., Semashko, T. A., Govorun, V. M., and
Koksharova, O. A. (2018) Stress effects of cyanotoxin -methylamino-L-
alanine (BMAA) on cyanobacterial heterocyst formation and functional-
ity. Environ. Microbiol. Rep. 10, 369–377 CrossRef Medline
39. Bullwinkle, T., Lazazzera, B., and Ibba, M. (2014) quality control and in-
filtration of translation by amino acids outside of the genetic code. Annu.
Rev. Genet. 48, 149–166 CrossRef Medline
40. Keller, T. L., Zocco,D., Sundrud,M. S., Hendrick,M., Edenius,M., Yum, J.,
Kim, Y.-J., Lee, H.-K., Cortese, J. F., Wirth, D. F., Dignam, J. D., Rao, A.,
Yeo, C.-Y., Mazitschek, R., and Whitman, M. (2012) Halofuginone and
other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat. Chem.
Biol. 8, 311–317 CrossRef Medline
41. Ahel, I., Korencic, D., Ibba, M., and Söll, D. (2003) Trans-editing of mis-
charged tRNAs. Proc. Natl. Acad. Sci. U.S.A. 100, 15422–15427 CrossRef
Medline
42. Vo,M. N., Terrey,M., Lee, J.W., Roy, B., Moresco, J. J., Sun, L., Fu, H., Liu,
Q., Weber, T. G., Yates, J. R., Fredrick, K., Schimmel, P., and Ackerman,
S. L. (2018) ANKRD16 prevents neuron loss caused by an editing-defec-
tive tRNA synthetase. Nature 557, 510–515 CrossRef Medline
43. Lu, J., Bergert,M.,Walther, A., and Suter, B. (2014) Double-sieving-defec-
tive aminoacyl-tRNA synthetase causes proteinmistranslation and affects
cellular physiology and development. Nat. Commun. 5, 5650 CrossRef
Medline
44. Nangle, L. A., Motta, C. M., and Schimmel, P. (2006) Global effects of
mistranslation from an editing defect in mammalian cells. Chem. Biol. 13,
1091–1100 CrossRef Medline
45. Singh, S. P., Rastogi, R. P., Häder, D.-P., and Sinha, R. P. (2011) An im-
provedmethod for genomicDNA extraction from cyanobacteria.World J.
Microbiol. Biotechnol. 27, 1225–1230 CrossRef
46. Holman, K. M., Puppala, A. K., Lee, J. W., Lee, H., Simonović, M., and
Simonović, S. (2017) Insights into substrate promiscuity of human seryl-
tRNA synthetase. RNA 23, 1685–1699 CrossRef Medline
47. Wilkinson, A. J., Fersht, A. R., Blow, D. M., and Winter, G. (1983) Site-
directed mutagenesis as a probe of enzyme structure and catalysis: Ty-
rosyl-tRNA synthetase cysteine-35 to glycine-35 mutation. Biochemistry
22, 3581–3586 CrossRef Medline
48. Ledoux, S., and Uhlenbeck, O. C. (2008) [3-32P]-labeling tRNA with
nucleotidyltransferase for assaying aminoacylation and peptide bond for-
mation. Methods 44, 74–80 CrossRef Medline
49. Wolfson, A. D., andUhlenbeck, O. C. (2002)Modulation of tRNAAla iden-
tity by inorganic pyrophosphatase. Proc. Natl. Acad. Sci. U.S.A. 99,
5965–5970 CrossRef Medline
50. Roy, H., Ling, J., Alfonzo, J., and Ibba, M. (2005) Loss of editing activity
during the evolution of mitochondrial phenylalanyl-tRNA synthetase.
J. Biol. Chem. 280, 38186–38192 CrossRef Medline
51. Mohler, K., Mann, R., Bullwinkle, T. J., Hopkins, K., Hwang, L., Reynolds,
N.M., Gassaway, B., Aerni, H. R., Rinehart, J., Polymenis,M., Faull, K., and
Ibba,M. (2017) Editing ofmisaminoacylated tRNA controls the sensitivity
of amino acid stress responses in Saccharomyces cerevisiae. Nucleic Acids
Res. 45, 3985–3996 CrossRef Medline
BMAA disrupts the function of human AlaRS
1410 J. Biol. Chem. (2020) 295(5) 1402–1410
